Evidence map›Paper›PMID 33591484›Full record

Trial reportCancer causes & control : CCC2021

The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer.

Sukh Makhnoon, Deborah J Bowen, Brian H Shirts, Stephanie M Fullerton, Eric B Larson, James D Ralston, Kathleen A Leppig, David R Crosslin, David Veenstra, Gail P Jarvik

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Cancer causes & control : CCC, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Primary and Secondary Prevention Interventions to Reduce Risk Factors Associated with Colorectal Cancer in High-Risk Groups: a Systematic Literature Review.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sukh MakhnoonDepartment of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Deborah J BowenDepartment of Bioethics and Humanities, University of Washington, Seattle, WA, USA. dbowen@uw.edu.
Brian H ShirtsDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA.
Stephanie M FullertonDepartment of Bioethics and Humanities, University of Washington, Seattle, WA, USA.
Eric B LarsonKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
James D RalstonGenetic Services, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Kathleen A LeppigGenetic Services, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
David R CrosslinDepartment of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA.
David VeenstraDepartment of Pharmacy, University of Washington, Seattle, WA, USA.
Gail P JarvikDepartments of Medicine (Medical Genetics) and Genome Sciences, University of Washington Medical Center, Seattle, WA, USA.
University of Washington · USKaiser Permanente Washington Health Research Institute · USUniversity of Washington Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Variation, Function, and Disease Supplement ProgramU01HG008657 · NHGRI · UNIVERSITY OF WASHINGTON · PI David Russell Crosslin, Gail Pairitz Jarvik · 2015 to 2026
$13.4M
Cancer Prevention and Research Institute of Texas RP170259NHGRI NIH HHS 3U01HG008657-02S1NHGRI NIH HHS U01 HG008657
6 · The paper itself

Abstract

As genetics gains favor in clinical oncology, it is important to address patient concerns around confidentiality, privacy, and security of genetic information that might otherwise limit its utilization. We designed a randomized controlled trial to assess the social impact of an online educational tool (FamilyTalk) to increase family communication about colorectal cancer (CRC) risk and screening. Of 208 randomized participants, 149 (71.6%) returned six-month surveys. Overall, there was no difference in CRC screening between the study arms. Privacy and confidentiality concerns about medical and genetic information, reactions to genetic test results, and lifestyle changes did not differ between arms. Participants with pathogenic or likely pathogenic (P/LP) and variant of uncertain significance (VUS) results were more likely than those with negative results to report that the results accurately predicted their disease risks (OR 5.37, p = 0.02 and OR 3.13, p = 0.02, respectively). This trial demonstrated no evidence that FamilyTalk impacted patient-reported outcomes. Low power, due to the limited number of participants with P/LP results in the overall sample, as well as the short follow-up period, could have contributed to the null findings.

Indexed as

AgedAged, 80 and overColorectal NeoplasmsCommunicationEarly Detection of CancerFemaleHumansMaleMass ScreeningMiddle AgedPatient Reported Outcome MeasuresRiskSurveys and QuestionnairesColorectal cancerConfidentialityElectronic medical recordGenetic testingPrivacyRandomized controlled trial

Identifiers

PMID33591484
OpenAlexW3130524497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.